Adagio Medical Holdings, Inc. 8K

Adagio Medical Holdings, Inc. announced second quarter 2026 results, including clinical and regulatory progress for its vCLAS ULTA platform and a higher quarterly net loss with no revenue and reduced cash balances.

On August 11, 2026, Adagio Medical Holdings, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting key clinical and regulatory milestones including the first patient treatment with its next‑generation vCLAS Ultra ultra‑low temperature ablation catheter under FDA Expanded Access, pivotal FULCRUM‑VT trial results demonstrating favorable safety and six‑month VT control outcomes, and the submission of a Premarket Approval application to the FDA for its vCLAS Ventricular Ablation System, while also disclosing a net loss of $6.7 million for the quarter, no revenue due to a pause in European commercial activity, and a decline in cash and cash equivalents to $7.7 million.

Filing Facts

CIK

2006986

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-093791

Alert Tier

6